Conservative lymph node surgery for patients with stage III melanoma: a prospective longitudinal cohort.

IF 4.2 2区 医学 Q1 ONCOLOGY
Oncologist Pub Date : 2025-09-01 DOI:10.1093/oncolo/oyaf212
David Moreno-Ramírez, Almudena Fernández-Orland, Blanca de-Unamuno, Lucía Jiménez-Puñal, Francisco M Almazán-Fernández, Aram Boada, Juan J Ríos-Martín, Rafael Botella-Estrada, Lara Ferrándiz
{"title":"Conservative lymph node surgery for patients with stage III melanoma: a prospective longitudinal cohort.","authors":"David Moreno-Ramírez, Almudena Fernández-Orland, Blanca de-Unamuno, Lucía Jiménez-Puñal, Francisco M Almazán-Fernández, Aram Boada, Juan J Ríos-Martín, Rafael Botella-Estrada, Lara Ferrándiz","doi":"10.1093/oncolo/oyaf212","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Therapeutic lymph node dissection has shown no clear benefits in terms of overall survival. However, appropriate regional control has repeatedly been reported in patients with lymph node metastasis.</p><p><strong>Objective: </strong>The objective of the study was to analyze the outcomes of a conservative surgical approach to patients with melanoma and lymph node metastasis detected either clinically or by imaging tests.</p><p><strong>Methods: </strong>A multicenter, prospective, longitudinal, single-arm cohort was conducted to recruit patients with melanoma who had 1-3 non-matted regional lymph node metastases (N1b, N2b) and were treated with conservative nodal surgery (conservative NS). The surgical procedure entailed resection of the metastatic lymph nodes identified, while preserving uninvolved lymph nodes in the regional basin. The patients received postoperative adjuvant immunotherapy according to routine clinical recommendations. The primary end-point was the 2-year regional lymph node recurrence-free survival (RRFS).</p><p><strong>Results: </strong>A total of 25 patients with lymph node metastasis underwent conservative NS to remove inguinal (44.00%) and axillary (56.00%) lymph node metastasis. During the follow-up, 36.00% (n = 9) of the patients developed recurrence in the regional basin treated with conservative NS. The 2-year RRFS was 65.70% (95% CI 46.30%-85.10%), and MSS was 78.10% (95% CI 60.85%-95.35%) at 2 years. Stage IIIB patients exhibited no statistically significant improvement in 2-year RRFS (83.30%) (log-rank P = .238). The short-term surgical complications reported were seroma (32%, n = 8), hematoma (8%, n = 2), and wound infection (4%, n = 1). No cases of lymphedema were observed.</p><p><strong>Conclusion: </strong>Conservative NS has the potential to prevent unnecessary complete lymph node dissections, particularly in clinical settings where neoadjuvant immunotherapy is not a suitable first-line therapeutic option.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449619/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf212","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Therapeutic lymph node dissection has shown no clear benefits in terms of overall survival. However, appropriate regional control has repeatedly been reported in patients with lymph node metastasis.

Objective: The objective of the study was to analyze the outcomes of a conservative surgical approach to patients with melanoma and lymph node metastasis detected either clinically or by imaging tests.

Methods: A multicenter, prospective, longitudinal, single-arm cohort was conducted to recruit patients with melanoma who had 1-3 non-matted regional lymph node metastases (N1b, N2b) and were treated with conservative nodal surgery (conservative NS). The surgical procedure entailed resection of the metastatic lymph nodes identified, while preserving uninvolved lymph nodes in the regional basin. The patients received postoperative adjuvant immunotherapy according to routine clinical recommendations. The primary end-point was the 2-year regional lymph node recurrence-free survival (RRFS).

Results: A total of 25 patients with lymph node metastasis underwent conservative NS to remove inguinal (44.00%) and axillary (56.00%) lymph node metastasis. During the follow-up, 36.00% (n = 9) of the patients developed recurrence in the regional basin treated with conservative NS. The 2-year RRFS was 65.70% (95% CI 46.30%-85.10%), and MSS was 78.10% (95% CI 60.85%-95.35%) at 2 years. Stage IIIB patients exhibited no statistically significant improvement in 2-year RRFS (83.30%) (log-rank P = .238). The short-term surgical complications reported were seroma (32%, n = 8), hematoma (8%, n = 2), and wound infection (4%, n = 1). No cases of lymphedema were observed.

Conclusion: Conservative NS has the potential to prevent unnecessary complete lymph node dissections, particularly in clinical settings where neoadjuvant immunotherapy is not a suitable first-line therapeutic option.

Abstract Image

Abstract Image

Abstract Image

保守淋巴结手术治疗iii期黑色素瘤患者:一项前瞻性纵向队列研究
背景:治疗性淋巴结清扫在总生存率方面没有明显的益处。然而,在淋巴结转移患者中,适当的局部控制已反复报道。目的:本研究的目的是分析保守手术方法治疗临床或影像学检查发现的黑色素瘤和淋巴结转移患者的结果。方法:采用多中心、前瞻性、纵向、单臂队列研究,招募1-3例非簇状区域淋巴结转移(N1b、N2b)并接受保守性淋巴结手术(保守性NS)治疗的黑色素瘤患者。手术过程需要切除已发现的转移性淋巴结,同时保留区域内未受累的淋巴结。术后患者按照常规临床建议接受辅助免疫治疗。主要终点为2年区域淋巴结无复发生存期(RRFS)。结果:25例淋巴结转移患者行保守性NS切除腹股沟(44.00%)和腋窝(56.00%)淋巴结转移。随访期间,36.00% (n = 9)患者在保守NS治疗的局部盆腔复发。2年RRFS为65.70% (95% CI 46.30%-85.10%), MSS为78.10% (95% CI 60.85%-95.35%)。IIIB期患者2年RRFS无统计学显著改善(83.30%)(log-rank p = 0.238)。报告的短期手术并发症为血肿(32%,n = 8)、血肿(8%,n = 2)和伤口感染(4%,n = 1)。未见淋巴水肿病例。结论:保守性NS有可能防止不必要的完全淋巴结清扫,特别是在新辅助免疫治疗不适合一线治疗选择的临床环境中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncologist
Oncologist 医学-肿瘤学
CiteScore
10.40
自引率
3.40%
发文量
309
审稿时长
3-8 weeks
期刊介绍: The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信